WO2001018202A3 - Flint analog compounds and formulations thereof - Google Patents

Flint analog compounds and formulations thereof Download PDF

Info

Publication number
WO2001018202A3
WO2001018202A3 PCT/US2000/020806 US0020806W WO0118202A3 WO 2001018202 A3 WO2001018202 A3 WO 2001018202A3 US 0020806 W US0020806 W US 0020806W WO 0118202 A3 WO0118202 A3 WO 0118202A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
flint analog
analog compounds
compounds
flint
Prior art date
Application number
PCT/US2000/020806
Other languages
French (fr)
Other versions
WO2001018202A2 (en
Inventor
Paul Robert Atkinson
Yu Tian
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Paul Robert Atkinson
Yu Tian
Derrick Ryan Witcher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Paul Robert Atkinson, Yu Tian, Derrick Ryan Witcher filed Critical Lilly Co Eli
Priority to EP00959164A priority Critical patent/EP1214411A2/en
Priority to AU70531/00A priority patent/AU7053100A/en
Publication of WO2001018202A2 publication Critical patent/WO2001018202A2/en
Publication of WO2001018202A3 publication Critical patent/WO2001018202A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides compounds, which comprise a protease-resistant FLINT analog complexed with a divalent metal cation, pharmaceutical formulations thereof, and methods of using such compounds for treating or preventing diseases related to the FasL/Fas interaction.
PCT/US2000/020806 1999-09-10 2000-08-31 Flint analog compounds and formulations thereof WO2001018202A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00959164A EP1214411A2 (en) 1999-09-10 2000-08-31 Flint analog compounds and formulations thereof
AU70531/00A AU7053100A (en) 1999-09-10 2000-08-31 Flint analog compounds and formulations thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15343399P 1999-09-10 1999-09-10
US60/153,433 1999-09-10

Publications (2)

Publication Number Publication Date
WO2001018202A2 WO2001018202A2 (en) 2001-03-15
WO2001018202A3 true WO2001018202A3 (en) 2001-09-07

Family

ID=22547206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020806 WO2001018202A2 (en) 1999-09-10 2000-08-31 Flint analog compounds and formulations thereof

Country Status (3)

Country Link
EP (1) EP1214411A2 (en)
AU (1) AU7053100A (en)
WO (1) WO2001018202A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2000058465A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2000058465A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU K-Y ET AL.: "A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 20, 14 May 1999 (1999-05-14), pages 13733 - 13736, XP002161940 *

Also Published As

Publication number Publication date
WO2001018202A2 (en) 2001-03-15
EP1214411A2 (en) 2002-06-19
AU7053100A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA01012184A (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria.
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
CA2317044A1 (en) Medicament for neurodegenerative diseases
AU7031500A (en) Therapeutic quinazoline compounds
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
WO2006004449A3 (en) A combination composition
BR0209812A (en) Use of osteopontin for the treatment and / or prevention of neurological diseases.
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
WO2001098279A3 (en) Bis-arylsulfones
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU6910600A (en) Methods for the treatment of mental disorders
WO1999059617A3 (en) Immunoregulator
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
GB9907571D0 (en) Compounds
EP0592903A3 (en) Use of ancrod for the preparation of drugs for the treatment of restenosis.
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
WO2001018202A3 (en) Flint analog compounds and formulations thereof
WO2001018041A3 (en) Flint proteins and formulations thereof
WO1999056697A3 (en) Pharmaceutical composition
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10069385

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000959164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000959164

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000959164

Country of ref document: EP